# Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

> **NCT01431339** · PHASE3 · COMPLETED · sponsor: **Durata Therapeutics Inc., an affiliate of Allergan plc** · enrollment: 739 (actual)

## Conditions studied

- Abscess
- Wound Infection
- Surgical Site Infection
- Cellulitis

## Interventions

- **DRUG:** IV Dalbavancin
- **DRUG:** Vancomycin/Linezolid

## Key facts

- **NCT ID:** NCT01431339
- **Lead sponsor:** Durata Therapeutics Inc., an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 739 (ACTUAL)
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431339, "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01431339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*